About the Client
Walter Bushnell is one of India’s established pharmaceutical organizations, known for delivering high-quality therapeutic solutions across multiple healthcare segments. With a strong presence in the Indian pharmaceutical market, the company has built a robust portfolio supported by stringent quality standards, regulatory compliance, and a wide distribution network. Its commitment to scientific rigor, patient safety, and regulatory excellence positions it as a trusted name in the healthcare ecosystem.
Workshop Objective
The objective of this program was to strengthen regulatory understanding and strategic decision-making capabilities among senior R&D leadership, specifically in the context of New Drug Applications (NDAs) and Supplemental NDAs (SNDAs). The training aimed to help participants:
- Understand the end-to-end regulatory framework governing drug approvals
- Build clarity on NDA and SNDA pathways, requirements, and submission strategies
- Strengthen decision-making related to safety, efficacy, and quality compliance
- Enable better alignment between R&D, regulatory, and commercial objectives
- Enhance awareness of global regulatory expectations and risk considerations
Workshop Summary
This focused, instructor-led workshop was delivered on-site for senior R&D leadership, designed to provide a comprehensive understanding of regulatory frameworks governing drug approvals. The session combined historical context, regulatory evolution, and practical application, enabling participants to connect regulatory requirements with real-world drug development challenges.
Key highlights included:
- Deep dive into the evolution of drug regulations driven by critical global incidents and their impact on current frameworks
- Structured understanding of New Drug definitions, regulatory expectations, and approval pathways
- End-to-end walkthrough of the drug development lifecycle — from discovery and pre-clinical stages to NDA filing and post-marketing surveillance
- Detailed coverage of regulatory concerns including safety, efficacy, quality, and risk-benefit evaluation
- Insights into IND processes, clinical trial phases, and data requirements for successful regulatory submissions
- Understanding of CMC (Chemistry, Manufacturing, and Controls) requirements and stability data expectations
- Practical discussions on aligning R&D strategy with regulatory compliance and approval timelines
- Interactive knowledge checks and scenario-based discussions to reinforce regulatory decision-making
The session concluded with participants gaining clarity on navigating complex regulatory pathways, enabling more structured and compliant approaches to drug development and approvals.
Workshop Details
Mode: On-Site
Audience: Senior R&D Leadership
Batch Size: 15 – 20 Participants
Duration: 1-day Workshop
Customized Training Modules
Certificates for all participants
Trainer Profile
- Senior pharmaceutical regulatory expert with extensive experience in drug development and regulatory affairs
- Deep expertise in NDA and SNDA processes, regulatory strategy, and compliance frameworks
- Strong background in CMC, clinical development pathways, and global regulatory requirements
- Experience working with pharmaceutical organizations on regulatory submissions and approvals
- Known for translating complex regulatory guidelines into practical, decision-oriented insights
- Specializes in aligning R&D, regulatory, and business strategies for successful drug commercialization
- Proven track record of delivering high-impact training programs for senior scientific and leadership audiences
- Brings a strong blend of technical depth and practical regulatory application
